Luther King Capital Management (LKCM)’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-65,534
| Closed | -$6.68M | – | 609 |
|
|
2023
Q2 | $6.68M | Hold |
65,534
| – | – | 0.03% | 177 |
|
|
2023
Q1 | $5.96M | Hold |
65,534
| – | – | 0.03% | 176 |
|
|
2022
Q4 | $2.49M | Hold |
65,534
| – | – | 0.01% | 277 |
|
|
2022
Q3 | $1.65M | Hold |
65,534
| – | – | 0.01% | 306 |
|
|
2022
Q2 | $1.99M | Sell |
65,534
-3,000
| -4% | -$89.5K | 0.01% | 296 |
|
|
2022
Q1 | $2.25M | Sell |
68,534
-9,925
| -13% | -$295K | 0.01% | 298 |
|
|
2021
Q4 | $2.07M | Sell |
78,459
-36,737
| -32% | -$2.84M | 0.01% | 308 |
|
|
2021
Q3 | $11.6M | Buy |
115,196
+3,325
| +3% | +$390K | 0.06% | 139 |
|
|
2021
Q2 | $15.8M | Buy |
111,871
+210
| +0.2% | +$23.7K | 0.08% | 129 |
|
|
2021
Q1 | $11.1M | Buy |
111,661
+12,705
| +13% | +$1.48M | 0.06% | 141 |
|
|
2020
Q4 | $12.2M | Buy |
98,956
+12,566
| +15% | +$1.65M | 0.07% | 132 |
|
|
2020
Q3 | $8.42M | Buy |
86,390
+4,244
| +5% | +$530K | 0.05% | 141 |
|
|
2020
Q2 | $12.8M | Buy |
82,146
+16,925
| +26% | +$2.57M | 0.09% | 120 |
|
|
2020
Q1 | $9.41M | Hold |
65,221
| – | – | 0.08% | 121 |
|
|
2019
Q4 | $13.3M | Sell |
65,221
-41,661
| -39% | -$7.6M | 0.09% | 126 |
|
|
2019
Q3 | $8.58M | Buy |
106,882
+7,337
| +7% | +$623K | 0.06% | 148 |
|
|
2019
Q2 | $9.39M | Buy |
99,545
+600
| +0.6% | +$51.8K | 0.07% | 148 |
|
|
2019
Q1 | $8.46M | Hold |
98,945
| – | – | 0.06% | 151 |
|
|
2018
Q4 | $5.55M | Buy |
98,945
+5,429
| +6% | +$331K | 0.05% | 164 |
|
|
2018
Q3 | $7.65M | Hold |
93,516
| – | – | 0.06% | 156 |
|
|
2018
Q2 | $3.27M | Buy |
93,516
+30,021
| +47% | +$914K | 0.03% | 229 |
|
|
2018
Q1 | $1.3M | Buy |
63,495
+5,837
| +10% | +$150K | 0.01% | 329 |
|
|
2017
Q4 | $1.63M | Hold |
57,658
| – | – | 0.01% | 311 |
|
|
2017
Q3 | $1.79M | Buy |
57,658
+1,676
| +3% | +$50.4K | 0.02% | 293 |
|
|
2017
Q2 | $1.77M | Hold |
55,982
| – | – | 0.02% | 293 |
|
|
2017
Q1 | $1.27M | Buy |
+55,982
| New | +$1.38M | 0.01% | 327 |
|
Other funds holding RETA
Luther King Capital Management (LKCM)'s RETA Position: Q3 2023 in Review
Luther King Capital Management (LKCM) sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 65,534 shares — an estimated $6.68M sold.
Luther King Capital Management (LKCM) first reported a position in RETA in Q1 2017 and held it in 26 quarters. The position peaked at $15.8M in Q2 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Luther King Capital Management (LKCM) reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Luther King Capital Management (LKCM) sold 65,534 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $6.68M.
- Luther King Capital Management (LKCM) first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2017 and held it in 26 quarters.
- Luther King Capital Management (LKCM)'s Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $15.8M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Luther King Capital Management (LKCM)'s 13F filing for Q3 2023, filed 13 Nov 2023.